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Abstract
Background: In an effort to identify new alternatives for long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFA)
supplementation, the effect of three sources of omega 3 fatty acids (algae, fish and Echium oils) on lipid profile and
inflammation biomarkers was evaluated in LDL receptor knockout mice.
Methods: The animals received a high fat diet and were supplemented by gavage with an emulsion containing
water (CON), docosahexaenoic acid (DHA, 42.89%) from algae oil (ALG), eicosapentaenoic acid (EPA, 19.97%) plus
DHA (11.51%) from fish oil (FIS), and alpha-linolenic acid (ALA, 26.75%) plus stearidonic acid (SDA, 11.13%) from
Echium oil (ECH) for 4 weeks.
Results: Animals supplemented with Echium oil presented lower cholesterol total and triacylglycerol concentrations
than control group (CON) and lower VLDL than all of the other groups, constituting the best lipoprotein profile
observed in our study. Moreover, the Echium oil attenuated the hepatic steatosis caused by the high fat diet.
However, in contrast to the marine oils, Echium oil did not affect the levels of transcription factors involved in lipid
metabolism, such as Peroxisome Proliferator Activated Receptor α (PPAR α) and Liver X Receptor α (LXR α),
suggesting that it exerts its beneficial effects by a mechanism other than those observed to EPA and DHA. Echium
oil also reduced N-6/N-3 FA ratio in hepatic tissue, which can have been responsible for the attenuation of steatosis
hepatic observed in ECH group. None of the supplemented oils reduced the inflammation biomarkers.
Conclusion: Our results suggest that Echium oil represents an alternative as natural ingredient to be applied in
functional foods to reduce cardiovascular disease risk factors.
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Background
The increased intake of omega-6 fatty acids during the
20th century as a result of an elevation in vegetal oil
consumption (of more than 1,000-fold) contributed to a
decline in the tissue concentration of long-chain n-3
polyunsaturated fatty acids (LC n-3 PUFA) [1,2], which
might be associated with the increased incidence of
inflammatory disorders, such as atherosclerosis [3]. The
development of atherosclerotic plaques is associated
with several clinical cardiovascular events. Considering
the health effects of LC n-3 PUFA toward the reduction
of cardiovascular disease (CVD) risk [4,5], many indus-
tries have added eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) from marine oils to food
formulations or supplements, aiming to explore this
health claim. In 2004, the Food and Drug Administra-
tion (FDA) qualified the health claim of products
containing EPA and DHA [6]. A similar recommenda-
tion was also provided by the American Heart Associ-
ation (AHA), who suggested consumption of 1 g/day of
EPA + DHA for patients with CVD and 2–4 g/day for
patients with hypertriglyceridaemia [7].
The cardioprotective effects of LC N-3 PUFA appear
to be due to a synergism between multiple mechanisms
including triacylglycerol (TG) lowering, improving mem-
brane fluidity, anti-inflammatory, antiarrhythmic and
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antithrombotic effects [5]. The scientific evidence
concerning the beneficial effects of the LC N-3 PUFA on
lipid profile and inflammation were obtained from
several studies using animal and human models. How-
ever, these effects and the mechanisms by which they
occur are restricted to the action of EPA and DHA [8].
Other non-marine sources of omega 3 fatty acids (N-3 FA),
such as alpha- linolenic acid (ALA) or stearidonic acid
(SDA), can be converted in vivo to EPA and DHA by the
desaturase and elongase enzymes in a tissue-dependent
manner, the liver being the major site of this conversion
[9]. It has been reported that the conversion rate of ALA is
low (5-10% for EPA and < 1% for DHA), which diminishes
the efficacy of these alternative sources in the reduction of
cardiovascular risk [10-12]. However, due to dietary prefe-
rences, safety, sustainability, cost and oxidative stability
aspects, other non-marine oils alternatives must be
evaluated [3,9-11,13,14]. It has been suggested that the
low rate by which ALA is converted to EPA is a result
of the limited activity of Δ6-desaturase when linoleic
acid (LNA) is also present [15]. However SDA, a pre-
cursor of EPA that is found in plants, such as Echium
(Echium plantagineum), black currant seed and other
genetically modified seeds, does not need Δ6-desaturase
activity to be converted into EPA [3,10]. In an effort to
identify new alternatives for LC N-3 PUFA supplementa-
tion, the objective of this study was to compare the effects
of three sources of N-3 FA (algae, fish and Echium oil)
on lipid composition and some inflammatory bio-
markers using LDL receptor deficient mice (LDLr
knockout mice) as model.
Methods
Oils and reagents
The N-3 FA used in this study were commercial products:
the algae oil containing 40% DHA (DHASCO) was
obtained from Martek BiosciencesW (Winchester, KY,
USA), the fish oil (EPA1T1600 MEG-3™) containing EPA
(20%) + DHA (12%) was obtained from Ocean NutritionW
(Dartmouth, NS, Canada) and the Echium oil containing
11.5% SDA (AW39144ECH) was obtained from Oil Seed
ExtractionW (Ashburton, New Zealand). All reagents were
purchased from Sigma Chemical Co. (St. Louis, MO,
USA), Merck (Darmstadt, Germany), Calbiochem Tech-
nology Inc. (Boston, MA, USA) and GE Healthcare (Little
Chalfont, Bucks, UK). The aqueous solutions were pre-
pared with ultra-pure Milli-Q water (Millipore Ind. Com.
Ltd., SP, Brazil), and the organic solvents were of HPLC
grade. Fatty acids profile of the oils used in this study was
analyzed by gas chromatography and is shown in Table 1.
Animals and diets
Forty male homozygous LDL receptor-deficient mice
(LDLr Knockout mice, C57BL/6) weighing 25–29 g
(4.0-4.5 months of age) were purchased from the
Faculty of Pharmaceutical Sciences (São Paulo, Brazil).
The mice were housed in plastic cages (5 animals/cage)
at constant temperature (22 ± 2°C) and relative humidity
(55 ± 10%), with a 12-h light–dark cycle. Food and water
were available ad libitum, and animals were divided
into four groups. All groups were fed with a high fat
diet for 4 weeks (Table 2), and were supplemented with
an oil-in-water emulsion (190 – 240 μL/d) per mouse
containing fish oil (FIS), algae oil (ALG), Echium oil
(ECH) or water (CON) by gavage. Amount of EPA,
DHA, SDA and ALA ingested from added oil per day is
presented in Table 3. We opted to compare the effect
of the same amount of EPA+DHA in all groups. To
achieve this objective the rate of conversion from SDA
to EPA (4:1) proposed by Whelan [16] was adopted in
our study. By this way, the EPA+DHA dosage applied
was 0.7, 0.8 and 0.7 mg/day using Fish, Alagae and
Echium oil respectively (Table 3). The emulsions were
prepared weekly by mixing the respective oil with water
using a high-pressure homogenizer (Homolab mod A-10,
Alitec, São Paulo, Brazil). The emulsions were prepared in
less than 2 minutes, and the temperature was kept below
40°C, during this short time. After, the emulsions were
transferred to 2 mL eppendorf tubes, immediately
Table 1 Fatty acids composition of the edible oils applied
in this study
Fatty acids (g/100 g total FA) Fish oil Algae oil Echium oil
C10:0 – capric - 1.12 -
C12:0 – lauric - 4.92 -
C14:0 – miristic 7.93 10.19 -
C16:0 – palmitic 17.05 6.97 5.15
C18:0 – stearic 3.05 0.92 2.57
C16:1 – palmitoleic 9.76 2.82 -
C18:1 - oleic (n-9) 13.20 27.48 12.77
C18:2 – (LNA) linoleic (n-6) 1.19 1.17 27.52
C18:3 – (ALA) α-linolenic (n-3) 0.68 - 26.75
C18:3 – (GLA) γ- linolenic (n-6) - - 13.11
C18:4 – (SDA) stearidonic (n-3) 3.28 - 11.13
C20:4- (ARA) arachidonic (n-6) 1.82 - -
C20:5 – (EPA) eicosapenatenoic (n-3) 19.97 - -
C22:5 – (DPA) docosapentaenoic (n-3) 2.20 0.38 -
C22:6 – (DHA) docosaexaenoic (n-3) 11.51 42.89 -
Σ saturated FA 28.03 24.12 7.72
Σ monounsaturated FA 22.96 30.30 12.77
Σ polyunsaturated FA 40.65 44.44 78.51
N-6 FA 3.01 1.17 40.63
N-3 FA 37.64 43.27 37.88
N-6/N-3 FA ratio 0.08 0.03 1.07
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immersed in nitrogen and kept at −80°C until the time of
gavage. All this procedure was repeated twice a week.
Emulsion characteristics are presented in Table 3. Diet
consumption was measured daily and animals were
weighed individually twice a week. After 4 weeks, the mice
were fasted for 12 h, and anaesthetised with a mixture
containing xylazine 2% (Sespo Ind. e Com. Ltda., Paulínia,
Brazil), ketamine (Syntec do Brasil Ltda., Cotia, Brazil) and
acepromazine (Vetnil Ind. e Com. de Prod. Veterinários
Ltda., Louveira, Brazil). Blood samples collected from the
brachial plexus were immediately centrifuged (1,600 × g
for 15 min at 4°C), frozen under liquid nitrogen and stored
(−80°C) for further analysis. The liver was excised, dried
with lint and weighed. Small pieces of the larger lobe were
frozen for Western blotting and further analysis, and a
piece of the smaller lobe was immersed in 10% buffered
formalin solution for histopathological examination. Subse-
quently, the animals were perfused with a cold NaCl solu-
tion (0.9%, 240.0 mL) via their left ventricle to remove the
excess of blood. The animal protocol was approved by the
Ethics Committee for Animal Studies of the Faculty of
Pharmaceutical Sciences (São Paulo, Brazil).
Measurements
Fatty acids were isolated from the liver and diets using
the extraction methodology proposed by the Association
of Official Analytical Chemists (method 996.06) [17].
The fatty acid methyl esters (FAME) were suspended in
hexane and analyzed by a gas chromatograph (GC17A
Shimadzu Class CG, Kyoto, Japan) equipped with a
30 m × 0.25 mm (i.d.), 0.25 μm film thickness fused si-
lica capillary column (Supelcowax, Bellefont, PA, USA)
and a flame ionization detector. Helium was used as a
carrier gas, and the fatty acids were separated using a
10°C/min gradient from 80 to 150°C and then a 6°C/min
gradient from 150°C to 230°C. Standard mixtures with
37 FAME and PUFA 3 methyl esters from Menhaden oil
(Sigma Chemical, St. Louis, MO, USA) was used to iden-
tify the peaks. The results were expressed as percentage
of the total fatty acids present.
The serum lipoprotein concentrations, including total
cholesterol, high density lipoprotein (HDL) and TG,
were quantified using an enzymatic colorimetric test
from Labtest (Lagoa Santa, MG, Brazil). The low density
Table 2 Composition and major fatty acids profile of the
high fat diet
Composition2 High fat diet1
Moisture (g/100 g) 7.22 ± 0.05
Ashes (g/100 g) 2.94 ± 0.10
Protein (g/100 g) 17.99 ± 0.49
Lipids (g/100 g) 30.72 ± 0.57
Carbohydrate (g/100 g) 41.13 ± 0.33
Energy (Kcal/100 g) 512.96 ± 3.32
Fatty acids (g/100 g total FA)
C10:0 – capric 0.81 ± 0.00
C12:0 - lauric 1.03 ± 0.17
C14:0 - miristic 1.68 ± 0.01
C16:0 - palmitic 26.20 ± 0.62
C18:0 - stearic 17.30 ± 0.05
C16:1 – palmitoleic 0.96 ± 0.07
C18:1 n-9 - oleic 32.73 ± 0.12
C18:2 – (LNA) linoleic (n-6) 11.94 ± 0.97
C18:3 – (ALA) α-linolenic (n-3) 0.60 ± 0.06
C18:3 – (GLA) γ- linolenic (n-6) 0.25 ± 0.06
C18:4 – (SDA) stearidonic (n-3) -
C20:0 - arachidic 0.27 ± 0.01
C20:1 - eicosaenoic (n-9) 0.59 ± 0.05
C20:2- eicosadienoic (n-6) 0.26 ± 0.02
C20:4- (ARA) arachidonic (n-6) -
C20:5 – (EPA) eicosapenatenoic (n-3) -
C22:5 – (DPA) docosapentaenoic (n-3) -
C22:6 – (DHA) docosaexaenoic (n-3) -
NI 5.15
1 Based on Safwat et al. [30].
2 Diet was composed by 187.0 g casein, 133.5 g sucrose, 300.0 g lard, 193.5 g
corn starch, 67.0 g cellulose, 53.5 g soybean oil, 46.5 g minerals, 2.4 g L-
cystine, 3.3 g choline bitartrate and 13.35 g vitamin mix/ kg diet.
NI, not identified.
Table 3 Characteristics of the emulsions prepared with
three N-3 FA sources
Emulsions
Characteristics1 Fish Algae Echium
Emulsion volume (μL/d) 240 190 270
Oil in the emulsion (%) 1 1 10
Oil supplementation (μL/d) 2.4 1.9 27.0
Oil supplementation (mg/d) 2.2 1.8 25.1
C20:5 – (EPA) eicosapenatenoic (n-3) (mg/d) 0.44 - -
C22:6 – (DHA) docosaexaenoic (n-3) (mg/d) 0.25 0.77 -
C18:4 – (SDA) stearidonic (n-3) (mg/d) 0.07 - 2.792
C18:3 – (ALA) linolenic (n-3) (mg/d) 0.01 - 6.71
C22:5 – (DPA) docosapentaenoic (n-3) (mg/d) 0.05 0.01 -
N-6 FA from gavage (mg/d) 0.07 0.02 10.20
N-3 FA from gavage (mg/d) 0.82 0.78 9.501
N-6 FA from diet (mg/d) 80.07 80.02 80.00
N-3 FA from diet (mg/d) 4.00 4.00 4.00
Total N-6 FA (mg/d) 80.07 80.02 90.20
Total N-3 FA (mg/d) 4.82 4.78 13.50
N-6/N-3 FA ratio 16.6 16.7 6.7
1 Supplementation is expressed as mg/d/animal.
2 Assumed no conversion from ALA to EPA and equivalence from SDA to EPA
of 25%, according to Whelan [16], resulting in about 0.70 mg/d.
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lipoprotein levels (LDL) and VLDL were estimated using
the Friedewald formula [18]. The inflammation biomarkers
(C-reactive protein (CRP), interleukin–6 (IL-6) vascular
cell-adhesion molecule-1 (VCAM), Inter-Cellular Adhesion
Molecule (ICAM) and adiponectin) were analysed in serum
samples using Multiplex commercial Kits (Millipore, St.
Charles, MO, USA).
Liver histology
The representative liver fragments were fixed in a 10% buff-
ered formalin solution for approximately 48 hours. Then,
the fragments were fixed in paraffin. The material was sub-
mitted to microtomy with a cut of 5 μm and stained with
hematoxylin and eosin for histopathological evaluation [19].
Western blotting analysis of hepatic peroxisome
proliferator activated receptor α (PPARα) and liver X
receptor α (LXRα)
The total nuclear protein was extracted from the frozen
liver tissue samples using the specific commercial Kit
NEPER (GE Healthcare, Little Chalfont, Bucks, UK).
Subsequently, 15 μg of the proteins present in the super-
natant was separated on a 10% SDS-PAGE gel and trans-
ferred to Amersham™ Hybond™-ECL™ nitrocellulose
membranes (GE Healthcare UK Ltd.-Amershan Place,
Little Chalfont, Buckinghamshire, UK) using a humid
system composed of buffer containing 25 mM Tris base,
192.0 mM glycine, 0.02% SDS, and 10% methanol (GE
Healthcare, Little Chalfont, Bucks, UK). The membranes
were then blocked with 5% ECL advance blocking agent
in TBST (Tris-buffered saline and Tween 20) for 1.5 h
to prevent the occurrence of nonspecific binding, and
they were incubated with primary antibodies (rabbit
polyclonal to LXRα – ab 82774 and rabbit polyclonal to
PPARα – ab 8934, ABCAM plc., Cambridge, MA, USA)
diluted in a ratio of 1:345 and 1:500, respectively. After
this step, the membranes were incubated for 1 h at 4°C
with a secondary antibody conjugated to horseradish
peroxidase (GE Healthcare, Little Chalfont, Bucks, UK).
Following three washes in TBST, the immunoreactive
bands were visualised using the ECL advance detection
system (Amersham Biosciences, Pittsburgh, PA, USA).
To standardise the immunoblots, a digital detection
system was applied (IMAGE QUANTTM 400 version
1.0.0, Amersham Biosciences, Pittsburgh, PA, USA) using
proliferating cell nuclear antigen – PCNA (ABCAM plc.,
Cambridge, MA, USA) as standard. The densitometry
was quantified using the Discovery series™ Quantity oneW
Analysis Software version 4.6.3 (Bio-Rad Laboratories Inc.,
Hercules, CA, USA).
Statistical analysis
The effect of each N-3 FA source on biomarkers was
compared by one-way ANOVA and Tukey HSD test.
Equivalent non-parametric ANOVA was applied when
there was no homogeneity of variances (Hartley test).
A probability value of 0.05 was adopted to reject the
null hypothesis. All calculations and graphs were
performed using the software Statistica v.9 (Statsoft
Inc., Tulsa, USA).
Results
All groups showed the same weight gain and diet
consumption (Table 4). Animals supplemented with
Echium oil presented lower total cholesterol and
triacylglycerol concentrations than Control, and lower
Table 4 Body weight, diet consumption, plasma lipid profile and inflammatory biomarkers observed in the
supplemented groups
CON FIS ALG ECH P1
Initial weight (g) 26.9 ± 1.3 26.8 ± 0.6 27.3 ± 0.1 27.8 ± 0.8 0.670
Final weight (g) 28.9 ± 2.0 28.3 ± 0.6 29.8 ± 1.4 28.8 ± 0.5 0.731
Weight gain (g) 2.0 ± 0.7 1.5 ± 0.0 2.5 ± 1.3 1.1 ± 1.3 0.542
Diet consumption (g/d/mouse) 2.3 ± 0.2 2.3 ± 0.1 2.3 ± 0.1 2.4 ± 0.3 0.886
Cholesterol (mg/100 mL) 371.7 ± 37.4a 349.8 ± 37.2ab 350.2 ± 56.3ab 312.9 ± 40.2b 0.040
LDL (mg/100 mL) 244.3 ± 32.2 240.4 ± 34.2 227.6 ± 50.4 199.3 ± 31.4 0.054
HDL (mg/100 mL) 95.9 ± 8.8 82.7 ± 13.7 95.0 ± 8.4 92.0 ± 13.7 0.050
VLDL (mg/100 mL) 29.7 ± 4.6a 26.7 ± 5.1a 27.6 ± 9.7 a 21.6 ± 3.5b 0.036
Triacylglicerol (mg/100 mL) 149.0 ± 23.6a 133.6 ± 25.4ab 115.8 ± 34.2b 109.1 ± 17.5 b 0.008
CRP (ng/mL) 121.6 ± 5.5 118.9 ± 6.7 118.0 ± 9.6 124.6 ± 8.6 0.232
IL-6 (pg/mL) 11.4 ± 2.3 10.6 ± 2.0 10.1 ± 1.9 11.2 ± 2.0 0.457
VCAM (pg/mL) 1.7 ± 0.4 1.7 ± 0.3 1.6 ± 0.5 1.3 ± 0.2 0.059
ICAM (ng/mL) 39.3 ± 6.7 36.9 ± 3.8 39.2 ± 4.4 35.4 ± 3.4 0.188
ADIPONECTIN (pg/mL) 13.9 ± 8.3 14.4 ± 6.0 11.5 ± 3.7 14.3 ± 9.3 0.805
1 Probability value obtained by ANOVA. Values followed by the same letter are not significantly different at the 0.05; a,b: p<0.05(n = 10/group).
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VLDL than all of the other groups, constituting the best
lipoprotein profile observed in this study. None of the
N-3 FA sources altered any of the inflammation bio-
markers (Table 4). The effect of N-3 FA associated with
high fat diet on the histological evaluation of the liver
tissue is presented in Figure 1. Hepatic steatosis can be
observed in the CON group with fatty infiltration
around the portal space. Fish and Echium oils attenu-
ated hepatic steatosis, whereas algae oil did not pro-
mote any protection against the hepatic steatosis
induced by the high fat diet. The N-3 FA must be present
in liver to exert their effects on lipid metabolism. Of the
main N-3 FA applied in our study (ALA, SDA, EPA and
DHA) (Figure 2), only EPA was observed in a higher
concentration in the liver homogenate of animals
supplemented with fish and Echium oils (Table 5).
Moreover, a lower omega 6/ omega 3 ratio (N-6/N-3
FA ratio) (p<0.001) was observed in liver of animals
supplemented with Echium oil (Table 5). In order to
better investigate the action of N-3 FA on the hepatic
steatosis, two transcription factors involved in lipid me-
tabolism were evaluated. Figures 3 and 4 present the
influence of the N-3 FA supplementation on the hep-
atic transcription factors LXRα and PPARα, which are
associated with fatty acids synthesis and oxidation,
respectively. Animals supplemented with algae oil
experienced a significant increase of PPARα expression
when compared to all other groups (Figure 3). A
decrease in LXRα expression was observed in the
groups supplemented with fish and algae oils (Figure 4),
whereas Echium oil did not alter any of these two tran-
scription factors.
Discussion
The three sources of N-3 FA fatty acids were effective
in improving the plasma lipid profile of the LDLr
knockout mice. Among them, Echium oil provided the
best results in terms of VLDL and total cholesterol re-
duction and contributed to the attenuation of hepatic
steatosis. None of these oils was able to reduce the in-
flammation caused by the high fat diet, according to
the biomarkers evaluated in this study.
The supplementation with fish and Echium oils in-
creased EPA concentrations in liver homogenate. The cap-
acity of SDA to increase EPA content in different tissues is
still controversial. Zhang et al. [20] reported that the sup-
plementation of LDLr knockout mice with Echium oil
(10% of total energy intake) resulted in a significant en-
richment of EPA in plasma lipids. According Harris [21]
the direct dietary intake of SDA has been proposed to be
another strategy to increase tissue EPA levels, since SDA
does not depend of Δ6-desaturase to be converted in EPA.
Figure 1 Representative photomicrographs of liver sections: (CON) - fatty infiltration around the portal space; (FIS) and (ECH) -
antisteatogenic effect exhibiting well-defined cells and low-fat vacuoles in the cytoplasm, and (ALG): hepatocytes presenting fatty
infiltration around the portal space. Original magnification 10X.
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LXRs and PPARs are nuclear receptors that play cru-
cial role in the regulation of fatty acid metabolism [22].
The hypolipidaemic effect of algae and fish oils has been
partially attributed to the downregulation of LXRα, with
a subsequent inhibition of fatty acid synthesis, associ-
ated with the upregulation of PPARα, which promotes
β-oxidation. Several studies have demonstrated that
EPA and DHA reduce TG and VLDL acting as PPARα
agonists and LXRα antagonists [5,23,24]. According to
Chilton et al. [3], SDA and EPA reduce the level of
mRNA for Sterol Regulatory Element-Binding Protein
1C (SREBP1c), Fatty Acid Synthase (FAS) and stearoyl
CoA desaturase 1 (SCD) in liver, suggesting that a possible
mechanism to explain TG reduction would be associated
with a decrease in the LXRα and consequently in the
genes that codify proteins involved in fatty acids hepatic
synthesis. This mechanism could be clearly observed to
the both marine oils applied in our study, but not to the
Echium oil. Animals supplemented with Echium oil
showed the most significant VLDL reduction and attenu-
ated steatosis, although no differences had been in regards
to LXRα and PPARα expression. In fact, the mechanisms
for the reduction of the plasma TG levels by Echium oil
are unknown. Although the dose applied in our study was
5-fold lower, our results agree with those reported by
Zhang et al. [20], who observed a reduction in TG and
Figure 2 Fatty acids content in the animal liver after the trial: (A) C18:3 – (ALA) α-linolenic (n-3), (B) C18:3 – (GLA) γ- linolenic (n-6);
(C) C20:5 – (EPA) eicosapenatenoic (n-3) and (D) C22:6 – (DHA) docosaexaenoic (n-3) - water (CON), fish oil (FIS), algae oil (ALG) and
Echium oil (ECH). Bars followed by the same upperscrit letter do not differ (P<0.05). Data are mean±SE (raw data).
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VLDL levels after Echium oil supplementation without
changes in PPARα and LXRα expression. These results
suggest that Echium oil can exert its beneficial effect on
lipid metabolism and hepatic steatosis via mechanisms
other than those reported for marine oils. In addition, it
has been recommended [25] that studies involving SDA
adopt a dose equivalent to EPA for supplementation.
However, when this procedure was carried out in our
study (Table 3), N-6/N-3 FA ratio of emulsion containing
Echium oil (6.7) became lower than emulsions with algae
Figure 3 Changes in PPARα expression after 4 weeks of supplementation - water (CON), fish oil (FIS), algae oil (ALG) and Echium oil
(ECH). *P<0.05.
Table 5 Major fatty acids composition in liver homogenate (g/100 g Total FA) observed in the supplemented groups
Fatty acids CON FIS ALG ECH P1
C14:0 – myristic acid 0.47 ± 0.08 0.46 ± 0.06 0.50 ± 0.08 0.41 ± 0.08 0.079
C16:0 – palmitic acid 26.37 ± 1.96 28.73 ± 4.15 27.60 ± 3.20 29.99 ± 3.91 0.163
C18:0 – stearic acid 12.11 ± 3.85 13.43 ± 4.98 10.50 ± 2.74 15.61 ± 6.43 0.107
C18:1- oleic acid 27.09 ± 6.25 26.4 ± 6.33 29.5 ± 4.87 22.15 ± 7.34 0.074
C18:2 – (LNA) linoleic (n-6) 12.87 ± 3.22 11.40 ± 4.82 12. 53 ±5.81 10.07 ± 4.64 0.584
C18:3 – (ALA) α-linolenic (n-3) 0.15 ± 0.13 0.14 ± 0.14 0.19 ± 0.12 0.26 ± 0.22 0.744
C18:3 – (GLA) γ-linolenic (n-6) 0.30 ± 0.05 0.35 ± 0.15 0.31 ± 0.11 0.34 ± 0.09 0.396
C20:4- (ARA) arachidonic (n-6) 6.69 ± 1.85 5.31 ± 1.46 4.80 ± 1.26 4.55 ± 1.22 0.060
C20:5 – (EPA) eicosapenatenoic (n-3) 0.12 ± 0.04a 0.17 ± 0.06ab 0.1 1± 0.05a 0.25 ± 0.04b 0.004
C22:6 –(DHA) docosahexaenoic (n-3) 2.98 ± 0.75 2.92 ± 0.96 2.8 1± 0.88 2.76 ± 0.92 0.951
N-6 FA 19. 86 ± 3.56b 17.06 ± 5.78ab 17.64 ± 6.61ab 14.97 ± 5.81a 0.017
N-3 FA 3.25 ± 0.70 3.23 ± 0.98 3.12 ± 0.95 3.27 ± 0.96 0.982
N-6/N-3 FA 6.11 ± 1.46a 5.27 ± 1.08a 5.65 ± 1.54a 4.58 ± 1.41b <0.001
1 Probability value obtained by ANOVA. Values followed by the same letter are not significantly different at the 0.05; a, b: p < 0.05 (n 6–10 animals/group).
Botelho et al. Lipids in Health and Disease 2013, 12:38 Page 7 of 10
http://www.lipidworld.com/content/12/1/38
(16.7) and fish (16.6) oils. Thus, differences observed in
biomarkers between ECH group and the other two
supplemented groups (ALG and FIS) can have also been
influenced by these difference in N-6/N-3 FA ratio.
Mice supplemented with Echium oil showed reduction
of N-6/N-3 ratio in liver (Table 5). According to Parker
et al. [26] the increase of N-6/N-3 FA ratio in liver is
associated with higher steatosis, since this condition can
favor lipogenesis and inflammation processes. These
findings have also been confirmed in human and animal
studies [27,28]. Thus, the lower N-6/N-3 FA ratio in
liver homogenate can have contributed to the attenu-
ation of steatosis observed in ECH group.
None of these three N-3 FA fatty acids sources was able
to reduce serum inflammatory biomarkers. Ishihara et al.
[29] observed that, in whole blood of Balb/c mice, the
production of Tumor Necrosis Factor - α (TNFα) was
suppressed by ALA, SDA and EPA supplementation.
However, the dose applied by the authors was 53-fold
higher than the dose used in our study. Our high-fat
diet was formulated on basis of the diet applied by
Safwat et al. [30] to promote hepatic steatosis in rats. The au-
thors observed that after 10 weeks, the animals developed
hepatic steatosis, insulin resistance, hypertriglyceridaemia,
and increased VLDL levels, but they observed no evi-
dence of hepatic inflammation or fibrosis, suggesting
that the hepatic steatosis was in its early stages. It is
possible that the dose of EPA, DHA and SDA used in our
study, although corresponding to an intake of 2 g/day for
humans, was not sufficient to reduce the inflammation
biomarkers when the process is at its initial steps. In spite
of this, the high N6/N3 FA ratio present in the diet (16:1),
typical of Western diet [5], may have annulled the poten-
tial LC N-3 PUFA anti-inflammatory action due to the
higher availability of ARA than EPA as substrate to the
oxidation mediated by cyclooxygenase and lipooxygenase
enzymes.
Conclusions
In our study, the supplementation with three different
sources of N-3 FA fatty acids was evaluated using LDLr
knockout animals fed with a high fat diet. It was ob-
served that the best combination of results, in terms of
plasma lipid profile and steatosis, was achieved by the
supplementation with Echium oil, and the mechanism
involved in this favourable result seems to be different
from those involved with EPA and DHA metabolism,
maybe due to the lower N-6/N-3 FA ratio present in the
Figure 4 Changes in LXRα expression after 4 weeks of supplementation- water (CON), fish oil (FIS), algae oil (ALG) and Echium oil
(ECH). **P<0.01.
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liver of animals supplemented with Echium oil. Theoret-
ically, it is possible to transfer a metabolic pathway for
EPA and DHA synthesis from a marine organism to an
oilseed crop plant [14]. However, while this option is not
available, our study confirms that Echium oil represents
an alternative as natural ingredient to be applied in func-
tional foods to reduce cardiovascular disease risk.
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